Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 1.4 %

Shares of CARA opened at $0.46 on Monday. The firm has a market cap of $25.43 million, a price-to-earnings ratio of -0.26 and a beta of 0.64. The company’s fifty day moving average is $0.30 and its 200-day moving average is $0.32. Cara Therapeutics has a 12 month low of $0.23 and a 12 month high of $1.15.

Hedge Funds Weigh In On Cara Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Disciplined Growth Investors Inc. MN increased its holdings in shares of Cara Therapeutics by 6.6% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 120,660 shares during the last quarter. XTX Topco Ltd bought a new stake in Cara Therapeutics during the third quarter worth approximately $29,000. Finally, FMR LLC grew its holdings in Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the last quarter. 44.66% of the stock is currently owned by institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.